Orient Pharma (4166) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 友霖

Orient Pharma (4166) reported revenue of NT$148 million for Oct 2026, -1.3% year on year and -0.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.3 billion (+17.5% year on year).

In Oct 2026, it ranked No. 56 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$90.6 million24/10Nov 2024 NT$108.7 millionDec 2024 NT$110.3 millionJan 2025 NT$131.5 millionFeb 2025 NT$91.6 million25/02Mar 2025 NT$93.8 millionApr 2025 NT$102.7 millionMay 2025 NT$114 millionJun 2025 NT$108.8 million25/06Jul 2025 NT$109.8 millionAug 2025 NT$100.9 millionSep 2025 NT$105.4 millionOct 2025 NT$150 million25/10Nov 2025 NT$160 millionDec 2025 NT$131.7 millionJan 2026 NT$145.4 millionFeb 2026 NT$78.2 million26/02Mar 2026 NT$107.6 millionApr 2026 NT$131 millionMay 2026 NT$113 millionJun 2026 NT$183 million26/06Jul 2026 NT$131.8 millionAug 2026 NT$115.9 millionSep 2026 NT$148.8 millionOct 2026 NT$148 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$148 million-1.3%-0.5%
Sep 2026NT$148.8 million+41.2%+28.4%
Aug 2026NT$115.9 million+14.9%-12.1%
Jul 2026NT$131.8 million+20.1%-28.0%
Jun 2026NT$183 million+68.3%+61.9%
May 2026NT$113 million-0.9%-13.8%
Apr 2026NT$131 million+27.6%+21.8%
Mar 2026NT$107.6 million+14.8%+37.6%
Feb 2026NT$78.2 million-14.6%-46.2%
Jan 2026NT$145.4 million+10.5%+10.4%
Dec 2025NT$131.7 million+19.4%-17.7%
Nov 2025NT$160 million+47.2%+6.7%
Oct 2025NT$150 million+65.7%+42.3%
Sep 2025NT$105.4 million+5.0%+4.5%
Aug 2025NT$100.9 million+0.1%-8.1%
Jul 2025NT$109.8 million+8.2%+0.9%
Jun 2025NT$108.8 million+7.6%-4.6%
May 2025NT$114 million+10.8%+11.0%
Apr 2025NT$102.7 million-15.1%+9.5%
Mar 2025NT$93.8 million-5.3%+2.4%
Feb 2025NT$91.6 million+17.3%-30.4%
Jan 2025NT$131.5 million+33.0%+19.2%
Dec 2024NT$110.3 million+21.7%+1.5%
Nov 2024NT$108.7 million+52.0%+20.0%
Oct 2024NT$90.6 million+10.3%-9.8%

Jan–Oct 2026 cumulative: NT$1.3 billion (+17.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Orient Pharma vs PEC / Orient Pharma vs Lotus Pharm / Orient Pharma vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16